reports
Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03
Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03 Amendment Extends NDA Acceptance Date PALATINE, Ill., March 01, 2022 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (“Agreement”) regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharmaceuticals, LLC (“AD Pharma”) to extend the FDA Acceptance Date for LTX-03 (“NDA Acceptance Date”) to December 31, 2022. The Company expects to complete clinical studies and other required steps to file the NDA and...
Acura Pharmaceuticals Provides Development Update on LTX-03
Acura Pharmaceuticals Provides Development Update on LTX-03 PALATINE, Ill., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced that the LTX-03 (hydrocodone bitartrate and acetaminophen) tablets using Acura’s LIMITx technology manufactured in the three New Drug Application (“NDA”) required registration batches successfully passed testing at the six month time point in an ongoing shelf life study when stored at normal temperature and humidity conditions, also known as controlled room temperature (“CRT”). The patented LIMITx technology is a compositio...
Acura Pharmaceuticals Announces Third Quarter 2021 Financial Results
Acura Pharmaceuticals Announces Third Quarter 2021 Financial Results PALATINE, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and nine months ended September 30, 2021. The Company reported revenues of $270 thousand, an operating loss of $531 thousand and a net loss of $262 thousand or $0.00 per diluted share for the third quarter 20...
Acura Pharmaceuticals Announces Second Quarter 2021 Financial Results
Acura Pharmaceuticals Announces Second Quarter 2021 Financial Results PALATINE, Ill., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and six months ended June 30, 2021. The Company reported revenues of $613 thousand and an operating loss of $300 thousand for the second quarter 2021 compared to revenues of $1.4 million and an operating income...
Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03
Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03 Amendment Extends NDA Acceptance Date PALATINE, Ill., July 26, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (“Agreement”) regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharma, LLC (“AD Pharma”) to extend the FDA Acceptance Date for LTX-03 (“NDA Acceptance Date”) to February 28, 2022. LTX-03 (hydrocodone with acetaminophen)Recent reports suggest growing numbers of legitimate pain patie...
- Jonathan Moreland
TREC TRECORA RESOURCES
REI RING ENERGY INC.
PTN PALATIN TECHNOLOGIES INC.
MNOV MEDICINOVA
HIBB HIBBETT SPORTS INC.
FULT FULTON FINANCIAL CORPORATION
EXLS EXLSERVICE HOLDINGS INC.
ACUR ACURA PHARMACEUTICALS INC.
CVM CEL-SCI CORP.
HOFT HOOKER FURNITURE CORP.
ACNB ACNB CORP.
AIRT AIR T INC.
GLV CLOUGH GLOBAL DIVIDEND AND INC
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
GLQ CLOUGH GLOBAL EQUITY FUND
NTIC NORTHERN TECHNOLOGIES INTERNATIONAL
SOR SOURCE CAPITAL INC.
ASPU ASPEN GROUP INC
BRN BARNWELL INDUSTRIES
DMLP DORCHESTER MINERALS L.P.
MTEM MOLECULAR TEMPLATES
TLRS TIMBERLINE RESOURCES CORP.
BHR BRAEMAR HOTELS & RESORTS
JEF JEFFERIES FINANCIAL GROUP INC.
ECOR ELECTROCORE
ANIX ANIXA BIOSCIENCES
GBCS GLOBAL HEALTHCARE REIT INC
LMST LIMESTONE BANCORP
KFS KINGSWAY FINANCIAL SERVICES
FULC FULCRUM THERAPEUTICS
GBX THE GREENBRIER COMPANIES
NML INC.
ASRV NEUBERGER BERMAN MLP INCOME FUND INC.
DCTH AMERISERV FINANCIAL
AFIB DELCATH SYSTEMS
IMRA ACUTUS MEDICAL
GCMG INC.
TURN IMARA
SOWG GCM GROSVENOR INC (A)
TPGY 180 DEGREE CAPITAL
VINC SOW GOOD INC.
FST TPG PACE BENEFICIAL FINANCE
USWS VINCERX INC
OBTX FAST ACQUISITION
MVF U S WELL SERVICES INC
IVAN EVERYTHING BLOCKCHAIN
MIND INC.
PECO BLACKROCK MUNIVEST FUND
S IVANHOE CAPITAL ACQUISITION
MITCHAM INDUSTRIES
INC.
PHILLIPS EDISON AND COMPANY
INC.
SENTINELONE
INC.
- Jonathan Moreland
TREC TRECORA RESOURCES
NRIM NORTHRIM BANCORP INC.
GLP GLOBAL PARTNERS LP
GCO GENESCO INC.
FBNC FIRST BANCORP (NORTH CAROLINA)
EXLS EXLSERVICE HOLDINGS INC.
DXPE DXP ENTERPRISES INC.
APTS PREFERRED APARTMENT COMMUNITIES INC.
ACUR ACURA PHARMACEUTICALS INC.
CVM CEL-SCI CORP.
EVA ENVIVA PARTNERS LP
QRHC QUEST RESOURCE HOLDING
CCLP CSI COMPRESSCO LP
CERC CERECOR INC
CLI MACK-CALI REALTY CORPORATION
RIGN TRANSOCEAN LTD.
SCOR COMSCORE INC.
CMT CORE MOLDING TECHNOLOGIES INC.
RRD R.R. DONNELLEY & SONS COMPANY
AFI ARMSTRONG FLOORING INC.
TSRI TSR
GBDC GOLUB CAPITAL BDC INC.
NHF NEXPOINT CREDIT STRATEGIES FUN
PLPC PREFORMED LINE PRODUCTS CO.
NICK NICHOLAS FINANCIAL INC.
ETTX ENTASIS THERAPEUTICS HOLDINGS
SLCA U.S. SILICA HOLDINGS
WLMS INC.
LMST WILLIAMS INDUSTRIAL SERVICES GROUP INC.
VABK LIMESTONE BANCORP
CYCN VIRGINIA NATIONAL BANKSHARES CORP
SAFE CYCLERION THERAPEUTICS
KFS SAFEHOLD INC.
PDSB KINGSWAY FINANCIAL SERVICES
XAIR PDS BIOTECHNOLOGY CORPORATION
HVBC BEYOND AIR
CBKM HV BANCORP
NRGX CONSUMERS BANCORP INC.
CTGO PIMCO ENERGY & TACTICAL CREDIT OPPORTUNITIES FUND
NOTV CONTANGO ORE INC.
WMPN INOTIV
ISIG INC.
WILLIAM PENN BANCORP
INSIGNIA SYSTEMS
- Jonathan Moreland
MNOV MEDICINOVA
MGNX MACROGENICS INC.
FULT FULTON FINANCIAL CORPORATION
EXLS EXLSERVICE HOLDINGS INC.
ACUR ACURA PHARMACEUTICALS INC.
JMP JMP GROUP LLC
RIGN TRANSOCEAN LTD.
NICK NICHOLAS FINANCIAL INC.
GMS GMS INC.
GIM TEMPLETON GLOBAL INCOME FUND
LMST LIMESTONE BANCORP
VAPO VAPOTHERM INC
ASRV AMERISERV FINANCIAL
WPF FOLEY TRASIMENE ACQUISITION
Acura Pharmaceuticals Announces Conversion of Debt
Acura Pharmaceuticals Announces Conversion of Debt PALATINE, Ill., June 14, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced that Abuse Deterrent Pharma, LLC (“AD Pharma”) has converted the entire principle and accrued interest of its Secured Promissory Note (the “Note”) with the Company into shares of the Company’s common stock. Effective with this conversion, the Note is retired and the Company is working with AD Pharma to release their security interest in all the Company’s assets. Under the terms of the Note, AD Pharma elected to convert the $6.9 mill...
Acura Pharmaceuticals Provides Development Update on LTX-03
Acura Pharmaceuticals Provides Development Update on LTX-03 PALATINE, Ill., June 07, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced the successful completion of three NDA required registration batches of the to-be-marketed LTX-03 formulation. The LTX-03 tablets were manufactured on commercial scale equipment and passed all requisite quality assurance tests. The LTX-03 tablets from these batches will be used in a six month shelf life stability study, which will commence immediately, and in human clinical studies, which will commence after an update to th...
Acura Pharmaceuticals Announces First Quarter Ended March 31, 2021 Fi...
Acura Pharmaceuticals Announces First Quarter Ended March 31, 2021 Financial Results PALATINE, Ill., May 17, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for its first quarter ended March 31, 2021. The Company reported an operating loss of $146 thousand for the first quarter 2021 compared to an operating loss of $483 thousand for the first quarter ended 2020. T...
Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Fina...
Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Financial Results PALATINE, Ill., March 31, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and twelve months ended December 31, 2020. The Company reported an operating loss of $0.1 million for the fourth quarter 2020 compared to an operating income of $0.3 million for the same period in ...
Acura Pharmaceuticals Announces Third Quarter 2020 Financial Results
Acura Pharmaceuticals Announces Third Quarter 2020 Financial Results PALATINE, Ill., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three and nine months ended September 30, 2020. The Company reported revenues of $410 thousand and an operating loss of $565 thousand for the third quarter 2020 compared to revenues o...
Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03
Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03 Amendment Extends NDA Acceptance Date and Expands Agreement PALATINE, Ill., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (“Agreement”) regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharmaceuticals, LLC (“AD Pharma”) to extend the FDA Acceptance Date for LTX-03 (“NDA Acceptance Date”), expand the product licenses, and revise the license payment schedule. Acura’s LIMITx™ techno...
Acura Pharmaceuticals Announces Second Quarter 2020 Financial Results
Acura Pharmaceuticals Announces Second Quarter 2020 Financial Results PALATINE, Ill., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three and six months ended June 30, 2020. The Company reported revenues of $1.4 million and an operating income of $421 thousand for the second quarter 2020 compared to revenues of...
Acura Pharmaceuticals Announces First Quarter 2020 Financial Results
Acura Pharmaceuticals Announces First Quarter 2020 Financial Results PALATINE, Ill., June 29, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three months ended March 31, 2020. The Company reported revenues of $1.1 million and an operating loss of $483 thousand for the first quarter 2020 compared to revenues of only $67 tho...
Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Fina...
Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results PALATINE, Ill., March 30, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three and twelve months ended December 31, 2019. The Company reported an operating income of $0.3 million for the fourth quarter 2019 compared to an operating loss of $0.3 million f...
Acura Pharmaceuticals Provides an Update on the Development of LTX-03
Acura Pharmaceuticals Provides an Update on the Development of LTX-03 PALATINE, Ill., March 23, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), today announced that Abuse Deterrent Pharma, LLC, its licensee of LTX-03 (Hydrocodone Bitartrate and Acetaminophen with Acura’s LIMITx™ Technology), has engaged Catalent Pharma Solutions, LLC (“Catalent”) to perform tablet manufacturing for clinical testing supplies of the product. Acura previously engaged Catalent to perform micro-particle process development for LTX-03 using hot-melt extrusion technology at Catalent’s Somers...
Acura Pharmaceuticals Announces Third Quarter 2019 Financial Results
Acura Pharmaceuticals Announces Third Quarter 2019 Financial Results PALATINE, Ill., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three and nine months ended September 30, 2019. The Company reported an operating income of $0.3 million for the third quarter 2019 compared to an operating loss of $1.0 million for the...
Acura Pharmaceuticals Announces Second Quarter 2019 Financial Results
Acura Pharmaceuticals Announces Second Quarter 2019 Financial Results PALATINE, Ill., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three and six months ended June 30, 2019. The Company reported an operating loss of $622 thousand for the second quarter 2019 compared to an operating loss of $1.25 million for the same period i...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.